Aventis/Sanofi Merger Would Dilute U.S. Presence: Sanofi Too "Insular," Aventis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While Aventis generates 38% of its sales from the U.S. market, the percentage would drop to 30% under a combined entity, the company says.
You may also be interested in...
Sanofi-Aventis In Talks With Pfizer And P&G About Exubera, Actonel Deals
Change-in-control triggers discussion about future of Aventis partnerships. Sanofi notes that there is a defined timeline for negotiations, but the company is not making any details public.
Sanofi-Aventis In Talks With Pfizer And P&G About Exubera, Actonel Deals
Change-in-control triggers discussion about future of Aventis partnerships. Sanofi notes that there is a defined timeline for negotiations, but the company is not making any details public.
Sanofi/Aventis Merger Would Not Affect Exubera, Actonel Agreements, Sanofi Says
Sanofi noted its track record with alliances and suggested that Aventis' partners could view the merger as a positive.